Shares of Oxford BioMedica plc (LON:OXB) reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as GBX 11.54 ($0.16) and last traded at GBX 10.94 ($0.15), with a volume of 23000000 shares. The stock had previously closed at GBX 10.94 ($0.15).
Separately, Peel Hunt reiterated a “buy” rating and issued a GBX 13 ($0.18) target price on shares of Oxford BioMedica in a research note on Monday.
In related news, insider Lorenzo Tallarigo purchased 30,436 shares of the firm’s stock in a transaction dated Monday, October 23rd. The shares were purchased at an average price of GBX 9 ($0.12) per share, with a total value of £2,739.24 ($3,714.73). Insiders bought a total of 90,662 shares of company stock worth $815,958 in the last three months.
About Oxford BioMedica
Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company’s segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners.
Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.